FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) is the only cell surface target to be leveraged for clinical benefit in men with advanced prostate cancer; however, PSMA expression is heterogeneous among patients and even within patients on a lesion-to-lesion basis (6).